Key result
Drug eluting stents appeared to reduce the incidence of in-stent restenosis compared with bare metal stents in cardiac allograft vasculopathy, though clinical endpoints were not different.
Why the study?
Do drug eluting stents reduce in stent restenosis in patients with cardiac allograft vasculopathy compared to bare metal stents?
Systematic Review (n=312)
Do drug eluting stents reduce in stent restenosis in patients with cardiac allograft vasculopathy compared to bare metal stents?
In patients with cardiac allograft vasculopathy, drug-eluting stents appear to reduce in-stent restenosis compared to bare-metal stents, though without clear differences in hard clinical outcomes.
Answers are grounded in this paper and cite their sources.
Supports DES over BMS to curb restenosis in cardiac allograft vasculopathy; extends angiographic data but leaves clinical benefit unresolved.
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a distinct pathological condition characterized by diffuse and progressive arteriopathy and it is an important determinant of long-term graft survival. Definitive CAV treatment is retransplantation but palliation with stenting might temporarily alleviate it. The benefit of drug eluting stents (DES) over bare metal stents (BMS) in the treatment of such lesions is debatable. We therefore sought to do a literature search to review the available evidence comparing DES to BMS. METHODS: We conducted Pub Med, EMBASE, Cochrane database review, Web of Science search of studies comparing DES with BMS in CAV. Available studies were retrospective in nature with either direct comparison groups (n = 5) or historical controls (n = 1). The main outcomes analyzed were in stent restenosis (ISR) during follow-up and clinical outcomes. RESULTS: A total of 312 patients from six studies were included in the review (1995-2007). Most commonly used DES were sirolimus eluting stent. DES appeared to reduce the long-term risk of ISR compared with BMS. Three of the five studies showed a statistically significant reduction in ISR at 12 months while the one study assessing ISR at 6 months showed no significant difference. Clinical endpoints such as death and major adverse cardiac events were not statistically different. CONCLUSION: DES appear to reduce the incidence of ISR in CAV as compared with BMS. Prospective randomized clinical trials are needed to determine the clinical benefit of DES beyond a reduction in ISR.
No takes yet. Share an insight, caveat, or question.
Dasari et al. (2011) conducted a systematic review in Cardiac allograft vasculopathy (n=312). Drug eluting stents vs. Bare metal stents was evaluated on In stent restenosis (ISR) and clinical outcomes (death and major adverse cardiac events). Drug eluting stents appeared to reduce the incidence of in-stent restenosis compared with bare metal stents in cardiac allograft vasculopathy, though clinical endpoints were not different.
Synapse has enriched 10 related papers. Consider them for comparative context: